Metohexal Succ (Metoprolol Succinate)

Metoprolol succinate selectively blocks β1‑adrenergic receptors in the heart, decreasing sympathetic stimulation. This leads to a slower heart rate, reduced contractility, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand, providing therapeutic benefit in the listed cardiovascular conditions.

The appropriate dose of Metohexal Succ is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and any comorbidities. Dosage may be started low and titrated upward, but exact regimens should only be set by a qualified healthcare professional.

Safety data for metoprolol succinate in pregnancy are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprolol succinate is a selective β1‑blocker, offering cardiac‑focused effects with fewer respiratory side effects compared with non‑selective agents like propranolol. Its extended‑release formulation provides once‑daily dosing, which can improve adherence relative to shorter‑acting beta‑blockers that require multiple daily doses.

Metohexal Succ should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Metohexal Succ is taken orally, usually as a whole tablet with or without food. Patients should swallow the tablet with a full glass of water and follow the dosing schedule prescribed by their healthcare provider, avoiding crushing or chewing extended‑release tablets.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with obstructive airway disease, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience fainting, rapid weight gain, swelling of the legs, or any signs of an allergic response.

Metohexal Succ is contraindicated in patients with known hypersensitivity to metoprolol or any excipients, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, cardiogenic shock, or overt decompensated heart failure. Caution is also advised for individuals with uncontrolled asthma or severe peripheral vascular disease.